These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 23233617)

  • 1. Childhood immune thrombocytopenia: role of rituximab, recombinant thrombopoietin, and other new therapeutics.
    Journeycake JM
    Hematology Am Soc Hematol Educ Program; 2012; 2012():444-9. PubMed ID: 23233617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New treatment options for primary immune thrombocytopenia].
    Gudbrandsdottir S; Frederiksen H; Birgens HS; Nielsen CH; Nielsen OJ; Stentoft J; Hasselbalch HC
    Ugeskr Laeger; 2011 Jan; 173(4):271-4. PubMed ID: 21262171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment outcome of immune thrombocytopenia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2012 Oct; 153(41):1613-21. PubMed ID: 23045311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ITP and international guidelines: what do we know, what do we need?
    Rodeghiero F; Ruggeri M
    Presse Med; 2014 Apr; 43(4 Pt 2):e61-7. PubMed ID: 24656296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.
    Kuter DJ; Mathias SD; Rummel M; Mandanas R; Giagounidis AA; Wang X; Deuson RR
    Am J Hematol; 2012 May; 87(5):558-61. PubMed ID: 22460421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.
    Vianelli N; Auteri G; Buccisano F; Carrai V; Baldacci E; Clissa C; Bartoletti D; Giuffrida G; Magro D; Rivolti E; Esposito D; Podda GM; Palandri F
    Ann Hematol; 2022 May; 101(5):963-978. PubMed ID: 35201417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of immune thrombocytopenic purpura in adults.
    Bussel J
    Semin Hematol; 2006 Jul; 43(3 Suppl 5):S3-10; discussion S18-9. PubMed ID: 16815346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune thrombocytopenia.
    Bussel J; Cooper N; Boccia R; Zaja F; Newland A
    Expert Rev Hematol; 2021 Nov; 14(11):1013-1025. PubMed ID: 34720027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of immune thrombocytopenia in France before the era of thrombopoietin receptor agonists].
    Michel M; Doz M; Leclerc-Teffahi S; Detournay B; Lévy-Bachelot L
    Rev Med Interne; 2012 Jun; 33(6):305-10. PubMed ID: 22444115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review.
    Rodrigo C; Gooneratne L
    J Thromb Haemost; 2013 Nov; 11(11):1946-53. PubMed ID: 23927583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Childhood immune thrombocytopenia: a changing therapeutic landscape.
    Breakey VR; Blanchette VS
    Semin Thromb Hemost; 2011 Oct; 37(7):745-55. PubMed ID: 22187397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New treatment methods for autoimmune thrombocytopenia].
    Koene HR
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2609-14. PubMed ID: 18161261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics.
    Liebman HA; Pullarkat V
    Hematology Am Soc Hematol Educ Program; 2011; 2011():384-90. PubMed ID: 22160062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for the treatment of acute refractory ITP.
    Kim SG; Whyte D; Pashankar FD
    J Pediatr Hematol Oncol; 2014 Apr; 36(3):e149-51. PubMed ID: 23669737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the management of immune thrombocytopenic purpura in children.
    Tarantino MD; Bolton-Maggs PH
    Curr Opin Hematol; 2007 Sep; 14(5):526-34. PubMed ID: 17934363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights and therapeutics for immune-mediated thrombocytopenia.
    Metjian A; Abrams CS
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):71-84. PubMed ID: 18095908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab efficacy in the treatment of children with chronic immune thrombocytopenic purpura.
    Ansari Sh; Rostami T; Yousefian S; Kiumarsi A; Miri-Aliabad G; Ramim T
    Pediatr Hematol Oncol; 2014 Sep; 31(6):555-62. PubMed ID: 25007304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current therapies in primary immune thrombocytopenia.
    Pels SG
    Semin Thromb Hemost; 2011 Sep; 37(6):621-30. PubMed ID: 22102265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of children with chronic immune thrombocytopenic purpura and Evans syndrome treated with rituximab.
    Gokcebay DG; Tavil B; Fettah A; Yarali N; Azik FM; Tunc B
    Clin Appl Thromb Hemost; 2013; 19(6):663-7. PubMed ID: 22815318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab-induced interstitial lung disease in a patient with immune thrombocytopenia purpura.
    Child N; O'Carroll M; Berkahn L
    Intern Med J; 2012 Mar; 42(3):e12-4. PubMed ID: 22432995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.